You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTobramycin
Accession NumberDB00684  (APRD00582)
TypeSmall Molecule
GroupsApproved, Investigational
Description

An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species. [PubChem]

Structure
Thumb
Synonyms
3'-Deoxykanamycin b
Nebramycin 6
Nebramycin factir 6
Nebramycin-Faktor 6
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Tobracin (tn)
Tobramicina
Tobramicina
Tobramycin
Tobramycine
Tobramycinum
Tobrex (tn)
External Identifiers
  • Lilly 47663
  • SPRC-AB01
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aj-tobramycinliquid40 mgintramuscular; intravenousAgila Jamp Canada IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Bethkissolution300 mg/4mLrespiratory (inhalation)Chiesi USA, Inc.2013-04-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Jamp-tobramycinliquid40 mgintramuscular; intravenousJamp Pharma Corporation2014-03-11Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Kitabis Paksolution300 mg/5mLrespiratory (inhalation)Pari Respiratory Equipment2014-12-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nebcin Inj 1.2gm/30mlliquid1.2 gintramuscular; intravenousEli Lilly Canada Inc1986-12-312003-05-12Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nebcin Inj 10mg/mlliquid10 mgintramuscular; intravenousEli Lilly Canada Inc1975-12-312003-05-12Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nebcin Inj 10mg/ml (vantage Vial)liquid10 mgintravenousEli Lilly Canada Inc1989-12-311997-05-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nebcin Inj 40mg/mlliquid40 mgintramuscular; intravenousEli Lilly Canada Inc1975-12-312003-05-12Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nebcin Inj 60mgliquid60 mgintramuscular; intravenousEli Lilly Canada Inc1978-12-311998-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nebcin Inj 80mgliquid80 mgintramuscular; intravenousEli Lilly Canada Inc1978-12-311998-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-tobramycin 0.3% Ophthalmic Solutionliquid3 mgophthalmicPharmascience Inc1999-02-18Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Tobramycin 0.3%solution0.3 %ophthalmicSandoz Canada Incorporated2000-08-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-tobramycinsolution60 mginhalationTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobisolution300 mg/5mLoralNovartis Pharmaceuticals Corporation1997-12-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobisolution300 mginhalationNovartis Pharmaceuticals Canada Inc1999-04-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobi Podhalercapsule28 mginhalationNovartis Pharmaceuticals Canada Inc2011-05-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobi Podhalercapsule28 mg/1oral; respiratory (inhalation)Novartis Pharmaceuticals Corporation2013-03-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution300 mg/5mLoralSandoz Inc2014-07-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, powder, for solution1200 mg/30mLintravenousFresenius Kabi USA, LLC2005-11-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycin for Injectionpowder for solution1.2 gintravenousFresenius Kabi Canada Ltd1983-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin for Injection U.S.P.powder for solution1.2 gintravenousSterimax Inc2007-05-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Inhalation Solutionsolution300 mginhalationSandoz Canada IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Injectionsolution10 mgintramuscular; intravenousFresenius Kabi Canada Ltd2003-09-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Injectionsolution40 mgintramuscular; intravenousFresenius Kabi Canada Ltd1997-05-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Injection USPliquid40 mgintramuscular; intravenousSandoz Canada Incorporated1999-12-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Injection USPliquid10 mgintramuscular; intravenousSandoz Canada Incorporated1999-12-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Injection, USPsolution40 mgintramuscular; intravenousMylan Pharmaceuticals Ulc2012-07-18Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycin Ophthalmic Solution USP 0.3%liquid3 mgophthalmicBausch & Lomb Pharmaceuticals Inc.1999-09-012003-07-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobrexsolution/ drops3 mg/mLophthalmicAlcon Laboratories, Inc.1981-03-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobrexointment3 mg/gophthalmicRebel Distributors Corp1981-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobrexointment3 mg/gophthalmicSTAT RX LLC USA1981-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobrexointment3 mg/gophthalmicA S Medication Solutions Llc1981-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobrexointment3 mg/gophthalmicAlcon Laboratories, Inc.1981-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobrex 0.3% Ophthalmic Solliquid.3 %ophthalmicAlcon Canada Inc1981-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobrex Ophthalmic Ont 3mg/gmointment3 mgophthalmicAlcon Canada Inc1984-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobrexansolution0.3 %ophthalmicAlcon Canada IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tobramycinsolution0.3 %ophthalmicApotex Inc2002-09-18Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tobramycininjection40 mg/mLintramuscular; intravenousMylan Institutional LLC2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicRebel Distributors Corp1994-05-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicREMEDYREPACK INC.2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution10 mg/mLintramuscular; intravenousHospira, Inc.1991-04-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution40 mg/mLintravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution40 mg/mLintramuscular; intravenousAkorn, Inc.2014-09-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicUnit Dose Services1995-01-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution40 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2005-11-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicSTAT Rx USA LLC1996-01-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicLake Erie Medical DBA Quaity Care Products LLC1994-05-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicHenry Schein Inc.2015-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection1200 mg/30mLintravenousXellia Pharmaceuticals Ap S2014-04-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution10 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicMwi2015-03-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicRebel Distributors Corp1993-11-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution300 mg/5mLrespiratory (inhalation)Teva Pharmaceuticals USA Inc2013-11-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicProficient Rx LP1993-11-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicBlenheim Pharmacal, Inc.2015-05-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, powder, lyophilized, for solution1.2 g/30mLintravenousX Gen Pharmaceuticals, Inc.2001-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLoralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicMajor Pharmaceuticals1993-11-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, powder, lyophilized, for solution1.2 g/30mLintravenousX Gen Pharmaceuticals, Inc.2001-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection40 mg/mLintramuscular; intravenousMylan Institutional LLC2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicSandoz Inc.1995-01-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution40 mg/mLintravenousHospira, Inc.1992-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection40 mg/mLintramuscular; intravenousMylan Institutional LLC2008-03-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution300 mg/5mLoralAkorn, Inc.2014-05-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection40 mg/mLintramuscular; intravenousMylan Institutional LLC2008-03-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicBausch & Lomb Incorporated1993-11-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution3 mg/mLophthalmicH.J. Harkins Company, Inc.1993-11-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycininjection, solution40 mg/mLintramuscular; intravenousHospira, Inc.1991-04-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution300 mg/5mLrespiratory (inhalation)Amneal Pharmaceuticals of New York, LLC2014-07-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycinsolution/ drops3 mg/mLophthalmicAkorn, Inc.1996-01-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycin In Sodium Chlorideinjection, solution.8 mg/mLintravenousHospira, Inc.1990-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycin Sulfateinjection40 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycin Sulfateinjection40 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycin Sulfateinjection40 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tobramycin Sulfateinjection40 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AktobAkorn
AlveoterolTetrafarm
AmgyKobec
BactobSolitaire
BelbarmicinaQuimica Luar
Bideon BioticFecofar
BiopticBausch & Lomb
BramitobTorrex
GernebcinInfectopharm
NebcinLilly
ObracinEuroCept
TobracinOpso Saline
TobramaxinAlcon
Brand mixtures
NameLabellerIngredients
TobradexAlcon Laboratories, Inc.
Tobradex Oph OintmentAlcon Canada Inc
Tobradex Oph SusAlcon Canada Inc
Tobradex STAlcon Laboratories, Inc.
Tobramycin and DexamethasoneRebel Distributors Corp
ZyletBausch & Lomb Incorporated
Salts
Name/CASStructureProperties
Tobramycin Sulfate
Thumb
  • InChI Key: ZEUUPKVZFKBXPW-TWDWGCDDSA-N
  • Monoisotopic Mass: 565.226507049
  • Average Mass: 565.593
DBSALT000317
Categories
UNIIVZ8RRZ51VK
CAS number32986-56-4
WeightAverage: 467.5145
Monoisotopic: 467.259127807
Chemical FormulaC18H37N5O9
InChI KeyInChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N
InChI
InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
IUPAC Name
(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
SMILES
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,6-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Monosaccharide
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
PharmacodynamicsTobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa.
Mechanism of actionTobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
AbsorptionThe bioavailability of tobramycin may vary because of individual differences in nebulizer performance and airway pathology.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeThe elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.
ClearanceNot Available
ToxicityLD50=441mg/kg (s.c. in mice)
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9313
Blood Brain Barrier-0.9794
Caco-2 permeable-0.759
P-glycoprotein substrateSubstrate0.5933
P-glycoprotein inhibitor INon-inhibitor0.7579
P-glycoprotein inhibitor IINon-inhibitor0.9086
Renal organic cation transporterNon-inhibitor0.8412
CYP450 2C9 substrateNon-substrate0.8361
CYP450 2D6 substrateNon-substrate0.8333
CYP450 3A4 substrateNon-substrate0.6662
CYP450 1A2 substrateNon-inhibitor0.9052
CYP450 2C9 inhibitorNon-inhibitor0.9359
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9117
CYP450 3A4 inhibitorNon-inhibitor0.9728
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9398
Ames testNon AMES toxic0.7537
CarcinogenicityNon-carcinogens0.9469
BiodegradationNot ready biodegradable0.9052
Rat acute toxicity1.7638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9695
hERG inhibition (predictor II)Non-inhibitor0.7522
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
  • Akorn inc
  • Alcon universal ltd
  • Altana inc
  • Bausch and lomb pharmaceuticals inc
  • Novex pharma
  • Falcon pharmaceuticals ltd
  • Novartis pharmaceuticals corp
  • Eli lilly and co
  • Akorn strides llc
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Teva parenteral medicines inc
  • X gen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Solutionrespiratory (inhalation)300 mg/4mL
Liquidintramuscular; intravenous1.2 g
Liquidintravenous10 mg
Liquidintramuscular; intravenous60 mg
Liquidintramuscular; intravenous80 mg
Liquidophthalmic3 mg
Solutionophthalmic0.3 %
Solutioninhalation60 mg
Solutioninhalation300 mg
Solutionoral300 mg/5mL
Capsuleinhalation28 mg
Capsuleoral; respiratory (inhalation)28 mg/1
Ointmentophthalmic
Suspension/ dropsophthalmic
Suspensionophthalmic
Injectionintravenous1200 mg/30mL
Injection, powder, for solutionintravenous1200 mg/30mL
Injection, powder, lyophilized, for solutionintravenous1.2 g/30mL
Injection, solutionintramuscular; intravenous10 mg/mL
Injection, solutionintramuscular; intravenous40 mg/mL
Injection, solutionintravenous40 mg/mL
Solutionophthalmic3 mg/mL
Solutionoral3 mg/mL
Solutionrespiratory (inhalation)300 mg/5mL
Powder for solutionintravenous1.2 g
Injection, solutionintravenous.8 mg/mL
Solutionintramuscular; intravenous10 mg
Liquidintramuscular; intravenous10 mg
Liquidintramuscular; intravenous40 mg
Solutionintramuscular; intravenous40 mg
Injectionintramuscular; intravenous40 mg/mL
Ointmentophthalmic3 mg/g
Solution/ dropsophthalmic3 mg/mL
Liquidophthalmic.3 %
Ointmentophthalmic3 mg
Prices
Unit descriptionCostUnit
Tobi (1 Box = 56, 5ml Ampules = 280ml Total) 280ml Plastic Container4461.42USD plastic
Tobramycin 1.2 gm vial338.25USD vial
TobraDex 0.3-0.1% Suspension 10ml Bottle200.43USD bottle
TobraDex 0.3-0.1% Ointment 3.5 gm Tube126.67USD tube
TobraDex 0.3-0.1% Suspension 5ml Bottle98.11USD bottle
Tobrex 0.3% Ointment 3.5 gm Tube80.02USD tube
Tobrex 0.3% Solution 5ml Bottle67.58USD bottle
TobraDex 0.3-0.1% Suspension 2.5ml Bottle54.99USD bottle
Tobramycin sulfate powder53.55USD g
Tobradex eye drops19.27USD ml
Tobi 300 mg/5 ml solution17.58USD ml
Tobramycin Sulfate 0.3% Solution 5ml Bottle15.99USD bottle
Tobrex 0.3% eye drops13.0USD ml
Tobi 60 mg/ml Solution11.4USD ml
Tobramycin Sulfate 40 mg/ml Solution3.6USD ml
Tobramycin 40 mg/ml3.14USD ml
Tobramycin 0.3% eye drops2.99USD ml
Aktob 0.3% eye drops2.85USD ml
Tobrex 0.3 % Ointment2.66USD g
Tobramycin 10 mg/ml2.26USD ml
Tobrex 0.3 % Solution1.88USD ml
Pms-Tobramycin 0.3 % Solution1.05USD ml
Sandoz Tobramycin 0.3 % Solution1.05USD ml
Tobramycin 60 mg/50 ml ns0.19USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada24147372009-01-062021-06-26
United States51496941992-09-222009-09-22
United States55082691994-10-192014-10-19
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility1E+003 mg/mlNot Available
logP-5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility53.7 mg/mLALOGPS
logP-3ALOGPS
logP-6.5ChemAxon
logS-0.94ALOGPS
pKa (Strongest Acidic)12.54ChemAxon
pKa (Strongest Basic)9.83ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count10ChemAxon
Polar Surface Area268.17 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity106.69 m3·mol-1ChemAxon
Polarizability47.18 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Istvan Bakondi-Kovacs, “Metabolic controlled fermentation process for carbamoyl tobramycin production.” U.S. Patent US20020197683, issued December 26, 2002.

US20020197683
General ReferencesNot Available
External Links
ATC CodesJ01GB01S01AA12
AHFS Codes
  • 08:12.02
  • 52:04.04
PDB EntriesNot Available
FDA labelDownload (414 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
AlendronateTobramycin may increase the activities of Alendronate.
AmdinocillinThe serum concentration of Tobramycin can be decreased when it is combined with Amdinocillin.
AmoxicillinThe serum concentration of Tobramycin can be decreased when it is combined with Amoxicillin.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Tobramycin.
AmpicillinThe serum concentration of Tobramycin can be decreased when it is combined with Ampicillin.
Atracurium besylateTobramycin may increase the activities of Atracurium besylate.
AvibactamAvibactam may increase the nephrotoxic activities of Tobramycin.
AzidocillinThe serum concentration of Tobramycin can be decreased when it is combined with Azidocillin.
AzlocillinThe serum concentration of Tobramycin can be decreased when it is combined with Azlocillin.
BacampicillinThe serum concentration of Tobramycin can be decreased when it is combined with Bacampicillin.
BenzylpenicillinThe serum concentration of Tobramycin can be decreased when it is combined with Benzylpenicillin.
Botulinum Toxin Type ATobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tobramycin.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Tobramycin.
CarbenicillinThe serum concentration of Tobramycin can be decreased when it is combined with Carbenicillin.
CarboplatinTobramycin may increase the ototoxic activities of Carboplatin.
CefaclorCefaclor may increase the nephrotoxic activities of Tobramycin.
CefdinirCefdinir may increase the nephrotoxic activities of Tobramycin.
CefepimeCefepime may increase the nephrotoxic activities of Tobramycin.
CefiximeCefixime may increase the nephrotoxic activities of Tobramycin.
CefmenoximeCefmenoxime may increase the nephrotoxic activities of Tobramycin.
CefotaximeCefotaxime may increase the nephrotoxic activities of Tobramycin.
CefotetanCefotetan may increase the nephrotoxic activities of Tobramycin.
CefoxitinCefoxitin may increase the nephrotoxic activities of Tobramycin.
CefpodoximeCefpodoxime may increase the nephrotoxic activities of Tobramycin.
CefprozilCefprozil may increase the nephrotoxic activities of Tobramycin.
CeftazidimeCeftazidime may increase the nephrotoxic activities of Tobramycin.
CeftibutenCeftibuten may increase the nephrotoxic activities of Tobramycin.
CeftriaxoneCeftriaxone may increase the nephrotoxic activities of Tobramycin.
CefuroximeCefuroxime may increase the nephrotoxic activities of Tobramycin.
CelecoxibCelecoxib may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Cisatracurium besylateTobramycin may increase the activities of Cisatracurium besylate.
CisplatinCisplatin may increase the nephrotoxic activities of Tobramycin.
ClavulanateThe serum concentration of Tobramycin can be decreased when it is combined with Clavulanate.
ClodronateTobramycin may increase the activities of Clodronate.
CloxacillinThe serum concentration of Tobramycin can be decreased when it is combined with Cloxacillin.
ColistimethateTobramycin may increase the nephrotoxic activities of Colistimethate.
ColistinTobramycin may increase the nephrotoxic activities of Colistin.
CyclacillinThe serum concentration of Tobramycin can be decreased when it is combined with Cyclacillin.
CyclosporineTobramycin may increase the nephrotoxic activities of Cyclosporine.
DiclofenacDiclofenac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
DicloxacillinThe serum concentration of Tobramycin can be decreased when it is combined with Dicloxacillin.
DiflunisalDiflunisal may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Tobramycin.
Ethacrynic acidThe risk or severity of adverse effects can be increased when Ethacrynic acid is combined with Tobramycin.
EtodolacEtodolac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
FenoprofenFenoprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
FloctafenineFloctafenine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
FlucloxacillinThe serum concentration of Tobramycin can be decreased when it is combined with Flucloxacillin.
FlurbiprofenFlurbiprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
FoscarnetFoscarnet may increase the nephrotoxic activities of Tobramycin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Tobramycin.
HetacillinThe serum concentration of Tobramycin can be decreased when it is combined with Hetacillin.
IbandronateTobramycin may increase the activities of Ibandronate.
IbuprofenIbuprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
IndomethacinIndomethacin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
InfliximabInfliximab may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
KetoprofenKetoprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacKetorolac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
MannitolMannitol may increase the nephrotoxic activities of Tobramycin.
MecamylamineTobramycin may increase the neuromuscular blocking activities of Mecamylamine.
Mefenamic acidMefenamic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
MeloxicamMeloxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
MeticillinThe serum concentration of Tobramycin can be decreased when it is combined with Meticillin.
MezlocillinThe serum concentration of Tobramycin can be decreased when it is combined with Mezlocillin.
NabumetoneNabumetone may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
NafcillinThe serum concentration of Tobramycin can be decreased when it is combined with Nafcillin.
NaproxenNaproxen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
OxacillinThe serum concentration of Tobramycin can be decreased when it is combined with Oxacillin.
OxaprozinOxaprozin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
PamidronateTobramycin may increase the activities of Pamidronate.
PancuroniumTobramycin may increase the activities of Pancuronium.
PhenoxymethylpenicillinThe serum concentration of Tobramycin can be decreased when it is combined with Phenoxymethylpenicillin.
PiperacillinThe serum concentration of Tobramycin can be decreased when it is combined with Piperacillin.
PiroxicamPiroxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
PivampicillinThe serum concentration of Tobramycin can be decreased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Tobramycin can be decreased when it is combined with Pivmecillinam.
RisedronateTobramycin may increase the activities of Risedronate.
RocuroniumTobramycin may increase the activities of Rocuronium.
Sodium picosulfateThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Tobramycin.
SuccinylcholineTobramycin may increase the activities of Succinylcholine.
SulindacSulindac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TenofovirThe serum concentration of Tobramycin can be increased when it is combined with Tenofovir.
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TicarcillinThe serum concentration of Tobramycin can be decreased when it is combined with Ticarcillin.
TiludronateTobramycin may increase the activities of Tiludronate.
TolmetinTolmetin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Tobramycin.
VancomycinVancomycin may increase the nephrotoxic activities of Tobramycin.
VecuroniumTobramycin may increase the activities of Vecuronium.
ZoledronateTobramycin may increase the activities of Zoledronate.
Food InteractionsNot Available

Targets

1. 30S ribosomal protein S12

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S12 P0A7S3 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. Pubmed
  4. Yang G, Trylska J, Tor Y, McCammon JA: Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies. J Med Chem. 2006 Sep 7;49(18):5478-90. Pubmed

2. 16S rRNA

Kind: Nucleotide

Organism: Enteric bacteria and other eubacteria

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Doi Y, de Oliveira Garcia D, Adams J, Paterson DL: Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother. 2007 Mar;51(3):852-6. Epub 2006 Dec 11. Pubmed
  4. Bogaerts P, Galimand M, Bauraing C, Deplano A, Vanhoof R, De Mendonca R, Rodriguez-Villalobos H, Struelens M, Glupczynski Y: Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J Antimicrob Chemother. 2007 Mar;59(3):459-64. Epub 2007 Jan 15. Pubmed
  5. Chen SY, Lin TH: A molecular dynamics study on binding recognition between several 4,5 and 4,6-linked aminoglycosides with A-site RNA. J Mol Recognit. 2009 Dec 22. Pubmed

Enzymes

1. Aminoglycoside 2'-N-acetyltransferase

Kind: Protein

Organism: Mycobacterium tuberculosis

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Aminoglycoside 2'-N-acetyltransferase P0A5N0 Details

References:

  1. Vetting MW, Hegde SS, Javid-Majd F, Blanchard JS, Roderick SL: Aminoglycoside 2’-N-acetyltransferase from Mycobacterium tuberculosis in complex with coenzyme A and aminoglycoside substrates. Nat Struct Biol. 2002 Sep;9(9):653-8. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11